secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001818382-22-000195
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte amends bylaws to strengthen director nomination rules and align with Delaware law
--------------------------------------------------------------------------------

- Board approved amended bylaws effective Dec 8, 2022, adding universal proxy rule compliance requirements (Rule 14a-19).
- Stockholders nominating directors must state intent to solicit proxies and provide evidence of compliance upon request.
- Company may disregard proxies/votes if nominating stockholder fails to meet Rule 14a-19 requirements.
- Bylaws updated for Delaware law: clarify virtual meeting adjournment procedures, eliminate stockholder list inspection requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838222000195/0001818382-22-000195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838222000195/huma-20221208.htm
  HTML page:      https://secwatch.observer/filing/0001818382-22-000195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer